Six of the drugs are awaiting FDA approval, and one (tezepelumab) just won approval. Here is a list:
- Adagrasib: a drug designed to treat colorectal cancer with the KRASG12C mutation, produced by Mirati Therapeutics and Zai Lab.
- Donanemab: a drug designed to slow cognitive decline, produced by Eli Lilly.
- Faricimab: a drug designed to treat patients with diabetic macular edema or wet age-related macular degeneration, produced by Roche and Chugai Pharmaceutical.
- Lecanemab: a drug designed to slow cognitive decline, produced by Eisai and Biogen.
- Tezepelumab: an asthma drug produced by Amgen and AstraZeneca.
- Tirzepatide: a drug designed to address weight loss and glycemic control, produced by Eli Lilly.
- Vutrisiran: a drug designed to treat ATTR, produced by Alnylam Pharmaceuticals.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
